ClinicalTrials.Veeva

Menu
L

Las Vegas Endocrinology | Henderson, NV

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3298176
sodium
RTA 901
Tirzepatide
TQJ230
Retatrutide
Inclisiran
LY3437943
BIIB143

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 13 total trials
New

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2)

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or o...

Not yet enrolling
Overweight
Type 1 Diabetes
Drug: Placebo
Drug: Tirzepatide

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting
Obesity
Drug: Retatrutide
Drug: Tirzepatide

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo
Locations recently updated

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period...

Enrolling
Thyroid Eye Disease
Other: Placebo
Biological: Teprotumumab

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Enrolling
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Drug: TQJ230
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Dexcom logo
Lilly logo
Novartis logo
Reata Pharmaceuticals logo
Amgen logo
MannKind logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems